One assignee leads the field with 433 of the 1,355 records in scope, far ahead of the fifth-place holder at 45. The top five assignees combined hold 80.0% of all records, and the top ten hold 88.0%, so the field is dominated by a small number of institutional and corporate portfolios rather than spread across many competitors. Anyone assessing freedom to operate should focus diligence on this small group first, since the long tail beyond the top ten contributes comparatively little volume individually.

Publication volume peaked at 80 records in 2021 and had fallen to 45 by 2024, a 44% decline over that span, which is the most recent year the data can treat as complete. That does not necessarily mean underlying research activity is shrinking — publication typically lags filing by about 18 months, so 2025 and 2026 figures are still filling in. The safer reading is that the core hydrocarbon-staple chemistry claims were staked out early, and filing has since moderated from its peak rather than accelerating further.

US20210061856A1, assigned to Dana-Farber Cancer Institute, Inc. and published 2021-03-04, covers cell-permeable stabilized peptide modules and methods for using them to deliver cargoes into cells. It sits within the broader cell-uptake and membrane-permeability claim territory that is well represented across this dataset’s A61K and C07K classes. Because it comes from one of the field’s most active assignees, any delivery-mechanism work using stapled or stabilized helical peptides should be checked against its specific claim language.